Chimeric antigen receptor T cell

CellOrigin Biotech announced strategic global collaboration with Qilu Pharmaceutical to develop "off-the-shelf" CAR-iMAC cell therapy

Retrieved on: 
Monday, September 5, 2022
Patient, Cancer, NK, IPSC, Macrophage, Chief executive officer, Zhejiang University, Chimeric antigen receptor T cell, API, GMP, Harvard University, Drug discovery, Industry, Drug development, Marketing, Hangzhou, Fine chemical, Pharmaceutical industry

HANGZHOU, China, Sept. 5, 2022 /PRNewswire/ --CellOrigin Biotech (Hangzhou) Co., Ltd. announced that it has made an agreement with Qilu Pharmaceutical on strategic global collaborations to develop, manufacture and commercialize a proprietary "off-the-shelf" iPSC-derived Chimeric Antigen Receptor Macrophages (CAR-iMAC) for cancer immnotherapy.

Key Points: 
  • HANGZHOU, China, Sept. 5, 2022 /PRNewswire/ --CellOrigin Biotech (Hangzhou) Co., Ltd. announced that it has made an agreement with Qilu Pharmaceutical on strategic global collaborations to develop, manufacture and commercialize a proprietary "off-the-shelf" iPSC-derived Chimeric Antigen Receptor Macrophages (CAR-iMAC) for cancer immnotherapy.
  • "We are excited to collaborate with Qilu Pharmaceutical because of its prestige in the Chinese pharmaceutical industry as well as its successful track record in new drug discovery.
  • It is an ideal strategic partner for novel cell therapy and it is our pleasure to collaborate with such a great biotech company."
  • Qilu Pharmaceutical is one of the leading vertically integrated pharmaceutical companies in China focusing on the development, manufacturing and marketing of active pharmaceutical ingredients (APIs) & finished formulations.

IEEE Open Journal of Engineering in Medicine and Biology Report Details Promise of New 3D Screening Tool for Accelerating Leading-edge Cancer Immunotherapies

Retrieved on: 
Thursday, August 25, 2022
Science, Research, Oncology, General Health, Health, Health Technology, University, Education, Neoplasm, University, Electrical engineering, Engineering, Technology, 3D, Research, Telecommunication, IEEE Engineering in Medicine and Biology Society, The Beatson Institute for Cancer Research, Digital library, Toxicity, Solution, Computer, Precision medicine, Chimeric antigen receptor T cell, Combination therapy, IEEE Biomedical Engineering Award, Electronic, Science, Cell, Method, Biomedical engineering, Human, Publication, Koch Institute for Integrative Cancer Research, University of Strathclyde, Cancer research, Pharmaceutical industry, Medical imaging, Medicine, Biology, IEEE

Researchers at the University of Glasgow and the Cancer Research UK Beatson Institute in Glasgow also contributed to the study.

Key Points: 
  • Researchers at the University of Glasgow and the Cancer Research UK Beatson Institute in Glasgow also contributed to the study.
  • We look forward to seeing its life-saving impact in preclinical drug testing and, ultimately, precision medicine in the clinic.
  • The IEEE Engineering in Medicine and Biology Society (EMBS) is the world's largest international society of Biomedical Engineers.
  • The IEEE Open Journal of Engineering in Medicine and Biology covers the development and application of engineering concepts and methods to biology, medicine and health sciences to provide effective solutions to biological, medical and healthcare problems.

Celularity Reports Second Quarter 2022 Financial Results and Corporate Update

Retrieved on: 
Tuesday, August 9, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Securities Act of 1933, Chimeric antigen receptor T cell, Risk, ASCO, CAR, Hematology, Private Securities Litigation Reform Act, MRD, Industry, GLOBE, American Society of Clinical Oncology, CELU, Annual general meeting, Securities Exchange Act of 1934, SEC, Cancer, Clinical trial, NK, IND, Board, HER2, Society, Security (finance), Research, Communication, IDH1, 3D ultrasound, AML, Income, Gilead Sciences, Patient, GBM, COVID-19, Kite Pharma, Genentech, Safety, Stomach, Acute leukemia, Treatment, Biology, Board of directors, Glioblastoma, Lymphoid leukemia, Insurance, CD16, Annual report, Amgen, Food, Russell, Terminology, Pharmaceutical industry, Vaccine, Reinsurance, Health insurance, Instituto de Biologia Molecular e Celular, Nasdaq

FLORHAM PARK, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced financial results for the second quarter ended June 30, 2022, and provided a corporate update.

Key Points: 
  • FLORHAM PARK, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies, today announced financial results for the second quarter ended June 30, 2022, and provided a corporate update.
  • In July 2022, Celularity announced that the first patient had been treated with CYNK-101 in the Phase 1 portion of the Phase 1/2a clinical trial in G/GEJ cancers.
  • Celularity submitted an investigational new drug application (IND) for CYCART-19 in the first quarter of 2022 and in May 2022, the FDA requested additional information before Celularity can proceed with the planned first-in-human Phase 1/2 clinical trial of CYCART-19.
  • If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements.

Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 8, 2022
FDA, Intellectual property, Woman, U.S. Securities and Exchange Commission, Chimeric antigen receptor T cell, State Administrative Expenses, CAR, Part, Lung cancer, Forward-looking statement, Trial of the century, GLOBE, R, Technology, Cancer, Infection, Incidence, Security (finance), Research, Patient, Therapy, COVID-19, Company, Acquisition, Breast cancer, Form 10-K, Vaccine, Safety, ATOS, Esophageal cancer, Transfusion-related acute lung injury, Nasdaq, Severe acute respiratory syndrome coronavirus 2, Proceedings of the Institution of Mechanical Engineers, Part B, Development, Administration, Adult, Pharmaceutical industry, Renewable energy, Medical imaging, Lithium, Atossa, Endoxifen, G&A

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2022, and provides an update on recent company developments.

Key Points: 
  • SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended June 30, 2022, and provides an update on recent company developments.
  • The FDA has issued a clinical hold letter requesting additional information which Atossa plans to submit by the end of the third quarter 2022 and to initiate enrollment in the fourth quarter 2022.
  • For the quarter ended June 30, 2022, Atossa had no source of sustainable revenue and no associated cost of revenue.
  • Six Months Ended June 30, 2022 Financial Results (in thousands):
    For the six months ended June 30, 2022, Atossa had no source of sustainable revenue and no associated cost of revenue.

ElevateBio Announces the Formation of a New Company With George Daley, M.D., Ph.D., and Boston Children’s Hospital to Develop iPSC-Derived Allogeneic Immune Therapies

Retrieved on: 
Thursday, August 4, 2022
Research, Hospitals, Genetics, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, IPSC, DLBCL, Hospital, Chimeric antigen receptor T cell, CAR, Industry, CD19, EZH1, Mountaineering, CEO, Boston, Ecosystem, Technology, Cancer, CGMP, B-cell lymphoma, TCR, LLC, Potency (pharmacology), Canadian Aviation Regulations, Gene editing, Blood, Good manufacturing practice, Lymphatic system, Patient, Cell, Haematopoiesis, Cell Stem Cell, RNA, Drug development, Longevity, Adult, Vaccine, Pharmaceutical industry, Mobile phone

ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced that it has formed a new company co-founded by George Daley, M.D, Ph.D., and Boston Childrens Hospital to develop allogeneic immune cell therapies based on a novel platform that generates functionally mature immune cells from induced pluripotent stem cells (iPSCs).

Key Points: 
  • ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced that it has formed a new company co-founded by George Daley, M.D, Ph.D., and Boston Childrens Hospital to develop allogeneic immune cell therapies based on a novel platform that generates functionally mature immune cells from induced pluripotent stem cells (iPSCs).
  • This is the first company to emerge from the previously announced five-year collaboration between Boston Childrens Hospital and ElevateBio to accelerate the development of novel cell and gene therapies.
  • CAR-T therapies have revolutionized the treatment of certain blood cancers, with complete responses in many patients undergoing this type of treatment.
  • In addition, BaseCamp is a purpose-built facility offering process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities.

ARM and NIIMBL Release Project A-Cell To Bring Quality By Design Principles To Cell-Based Therapy Manufacturing

Retrieved on: 
Tuesday, July 26, 2022
University college, Antibody, Gene therapy, GLOBE, Industry, Chimeric antigen receptor T cell, National Institute, Workforce, Technology transfer, FDA, VAX 9000, ARM, Science, Cancer, Patient, Lymphatic system, CMC, Quality by design, Regenerative medicine, Vaccine, Pharmaceutical industry, Chemistry

Many of the hurdles to the streamlined, cost-effective manufacture of cell and gene therapy products derive from a lack of standardized methodologies and training around CMC programs.

Key Points: 
  • Many of the hurdles to the streamlined, cost-effective manufacture of cell and gene therapy products derive from a lack of standardized methodologies and training around CMC programs.
  • A-Cell emulates previous QbD efforts that were applied to the manufacturing of monoclonal antibodies (A-Mab), vaccines (A-Vax), and more recently, gene therapies (A-Gene).
  • A-Cell focuses on an autologous CAR-T therapy because of early regulatory successes and significant investor interest in this therapeutic approach.
  • We are very excited about the project because cell therapies have demonstrated a transformational impact on patients, said Gene Schaefer, NIIMBL senior fellow.

European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation

Retrieved on: 
Thursday, July 21, 2022
Biotechnology, Surgery, Health, Pharmaceutical, Clinical Trials, Chronic kidney disease, MPH, U.S. Securities and Exchange Commission, Trial of the century, EC, HLA-A*02, Dialysis, FACC, Holm–Bonferroni method, Research, Cardiovascular disease, Chimeric antigen receptor T cell, Royal commission, Development, CAR, Kidney transplantation, Risk, European Medicines Agency, Therapy, Immune system, Safety, COVID-19, Cancer, Inflammation, Clinical trial, European Commission, Technology, Patient, Nasdaq, Regulatory T cell, Nephrotoxicity, Survival, Autoimmunity, Annual report, Pharmaceutical industry, Dentistry, Vaccine, Sangamo Therapeutics, MD

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Commission (EC) has granted Orphan Medicinal Product Designation (OMPD) to TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for treatment in solid organ transplantation.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the European Commission (EC) has granted Orphan Medicinal Product Designation (OMPD) to TX200, a wholly-owned autologous Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) cell therapy product candidate for treatment in solid organ transplantation.
  • Our goal with TX200 is to create a transformative therapy that reduces the risk of organ rejection, while reducing the patient burden from chronic immunosuppressive therapy.
  • The EC granted OMPD to TX200 following a positive opinion from the European Medicines Agencys Committee for Orphan Medicinal Products.
  • To qualify for orphan designation, a treatment must be intended for a life-threatening or chronically debilitating disease affecting fewer than 5 in 10,000 people.

Onward Therapeutics Made a Second Strategic Equity Investment in Emercell for Their NK Cell Technology in Cancer Immunotherapy

Retrieved on: 
Monday, June 20, 2022
ADI, Lymphatic system, NK, FUI, Drug development, Regenerative medicine, Technology, University Hospital Center Dr Dragiša Mišović, CEO, Lymphoma, Institute, ICM, Astellas Institute for Regenerative Medicine, CAR, Company, Cancer, Exercise, Natural killer T cell, Patient, Chimeric antigen receptor T cell, Therapy, Vaccine, Pharmaceutical industry, Épalinges, Biopôle

EPALINGES, Switzerland and MONTPELLIER, France, June 20, 2022 /PRNewswire/ --Onward Therapeutics SA (Onward Therapeutics) and Emercell SAS (Emercell) announced today the recent exercise of Onward Therapeutics' second of three instalments of equity investment in Emercell.

Key Points: 
  • EPALINGES, Switzerland and MONTPELLIER, France, June 20, 2022 /PRNewswire/ --Onward Therapeutics SA (Onward Therapeutics) and Emercell SAS (Emercell) announced today the recent exercise of Onward Therapeutics' second of three instalments of equity investment in Emercell.
  • Emercell has developed a platform technology to produce off-the-shelf natural killer (NK) cells.
  • NK-001 is an optimized cell therapy product consisting of highly activated and alloreactive allogeneic NK cells.
  • Onward Therapeutics is an oncology company focusing on the identification and development of innovative medicines for the treatment of cancer.

Serotiny Announces a Research Collaboration With Janssen to Optimize Designs for Chimeric Antigen Receptors Signaling Domains

Retrieved on: 
Monday, June 6, 2022
Professional Services, Oncology, Health, Venture Capital, Pharmaceutical, Biotechnology, CA, Mining, Janssen Pharmaceuticals, Chimeric antigen receptor T cell, Protein, Canadian Aviation Regulations, Johnson & Johnson, CAR, TMDP, Machine learning, Technology, Heart, Janssen, Engineering, Synthetic biology, Pharmaceutical industry, Fine chemical, Serotiny

Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, announced today a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to optimize CAR designs for cellular therapy.

Key Points: 
  • Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering, announced today a collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to optimize CAR designs for cellular therapy.
  • Were excited to be working with Janssen scientists, said Colin Farlow, J.D., Serotinys CEO.
  • Serotiny is located at the Johnson & Johnson Innovation JLABS incubator in South San Francisco, CA.
  • Serotiny is a pre-clinical discovery company building better gene and cell therapies through engineering Therapeutic Multi-Domain Proteins (tMDP) such as Chimeric Antigen Receptors (CARs), alternative CARs, accessory proteins and gene editing systems in high-throughput.

Serotiny Appoints Chad May, Ph.D., as Chief Scientific Officer

Retrieved on: 
Monday, May 23, 2022
Oncology, Health, Genetics, General Health, Pharmaceutical, Biotechnology, Cell biology, Knowledge, Engineering, Center for Research and Development in Health Sciences, Doctor of Philosophy, Weill Cornell Graduate School of Medical Sciences, Maverick, Leadership, Patient, Synthetic biology, Medicine, Sloan, Canadian Aviation Regulations, IND, TMDP, Chimeric antigen receptor T cell, Takeda, Protein, University, Technology, Chad, Eli Lilly, Heart, Machine learning, ImClone Systems, Medical device, Vaccine, Immunology, Serotiny, Research, Pfizer, Genetics

Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering for the next generation of cell and gene therapies, has appointed Chad May, Ph.D., as the company's Chief Scientific Officer.

Key Points: 
  • Serotiny, a leader in high-throughput therapeutic Multi-Domain Protein (tMDP) engineering for the next generation of cell and gene therapies, has appointed Chad May, Ph.D., as the company's Chief Scientific Officer.
  • In this new role, Dr. May will lead the research and development of Serotinys novel therapeutics programs.
  • "Chad is a fantastic addition to the Serotiny leadership team," said Serotiny Chief Executive Officer Colin Farlow.
  • Dr. May commented, "It is very exciting for me to be joining the innovative team at Serotiny.